The 340B Drug Pricing Program requires pharmaceutical companies to provide drugs at reduced prices to certain safety-net providers; however, drug companies can deny discounts for orphan drugs that treat rare diseases. This creates a loophole in the law that lets drug companies broadly define which drugs they discount, according to the report.
The Closing Loopholes for Orphan Drugs Act would lower drug prices for rural hospitals by clarifying the definition of an orphan drug, which would prevent companies from denying numerous discounts.
“Vermont’s community hospitals rely heavily on savings from federally mandated discounted prescription drugs to provide high quality affordable health care in the communities they serve. My legislation would close a loophole that allows drug companies to deny discounts for certain drugs,” Mr. Welch said in a press release.
More articles on healthcare finance:
6 largest gifts from individuals to healthcare organizations in 2017
4 of 37 provider-sponsored health plans profitable in 2015
Illinois ordered to increase Medicaid funding to providers during budget impasse
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
